OKUR OnKure Therapeutics, Inc.

NASDAQ
$2.82

OnKure Therapeutics, Inc. (OKUR) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.0% since its last earnings release on November 4, 2026.

OnKure Therapeutics Missed Consensus Estimates
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.30)
Rev est $500K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.88

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About OnKure Therapeutics, Inc.

OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.